MLSS
MILESTONE SCIENTIFIC INC.
$0.3800
-9.52%
$34.1M
No data for this timeframe.
Vol
Market Cap$34.1M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$675.0K
Inst. Activity0 buys / 1 sells
SEC Reports5
Press Releases2
Exchange NYSE·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. DE·CIK 0000855683·Prev Close $0.4200
Recent Activity
Jun 2, 2026
SEC
Milestone Scientific filed a resale S-3 shelf registration covering 15,925,926 shares (7,962,963 Initial Shares + 7,962,
S-3 — Impact 6/10
May 14, 2026
SEC
Milestone Scientific reported Q1 2026 EPS of -$0.01, in line with consensus, and revenue of $2.16M, slightly below the $
PRESS-RELEASE — Impact 4/10
May 6, 2026
SEC
Milestone Scientific dismissed CBIZ CPAs and hired Grassi & Co. as its new auditor effective May 15, 2026. The prior aud
8-K — Impact 4/10
Inst.
MORGAN STANLEY — TRIM
5,511 shares ($1.5K)
Inst.
MORGAN STANLEY — ADD
10,511 shares ($4.8K)
May 27, 2026
Press
Milestone Scientific highlighted a new peer-reviewed study in Operative Neurosurgery showing that its CompuFlo Epidural
Impact 4/10
May 27, 2026
fda
Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
<p align="justify">ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYS
Apr 21, 2026
Press
Milestone Scientific (MLSS) announced the closing of a $2.15 million private placement of common stock and warrants, wit
Impact 5/10
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$1.00 (Nov 2025)
Current $0.3860
Low $1.00
Median $1.00
High $1.00
2 analysts
$1.00
$1.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 20, 2025 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
| Nov 20, 2024 | Benchmark | REITERATE | Speculative Buy → Speculative Buy |
| Oct 10, 2024 | Benchmark | INITIATE | Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 | $-0.01 — $-0.01 | 50% YoY | 2 |
| Next Q | $-0.01 | $-0.01 — $-0.01 | 0% YoY | 2 |
| Current FY | $-0.04 ▲ +11.1% | $-0.04 — $-0.04 | 43% YoY | 2 |
| Next FY | $-0.04 ▲ +12.5% | $-0.04 — $-0.03 | 13% YoY | 2 |
Latest Reports
BEARISH
S-3
6/10
Milestone Scientific filed a resale S-3 shelf registration covering 15,925,926 shares (7,962,963 Initial Shares + 7,962,
Jun 2, 2026
NEUTRAL
Press
4/10
Milestone Scientific highlighted a new peer-reviewed study in Operative Neurosurgery showing that its CompuFlo Epidural
May 27, 2026
NEUTRAL
PRESS-RELEASE
4/10
Milestone Scientific reported Q1 2026 EPS of -$0.01, in line with consensus, and revenue of $2.16M, slightly below the $
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $641.4K | — |
| RENAISSANCE TECHNOLOGIES LLC | $22.6K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.4K | NEW |
| MORGAN STANLEY | $1.5K | TRIM |
| BANK OF AMERICA CORP | $157.00 | — |
5 institutional holders with $675.0K total value (2,472,700 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,349,317 | $641.4K | 95.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 82,897 | $22.6K | 3.4% | TRIM -38.4% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 34,400 | $9.4K | 1.4% | NEW |
| 4 | MORGAN STANLEY | 5,511 | $1.5K | 0.2% | TRIM -47.6% |
| 5 | BANK OF AMERICA CORP /DE/ | 575 | $157.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 10,511 | 5,511 | -47.6% | $1.5K | 2025-Q4 |
| MORGAN STANLEY | ADD | 5,512 | 10,511 | +90.7% | $4.8K | 2025-Q3 |
| UBS Group AG | TRIM | 13,100 | 4,986 | -61.9% | $2.3K | 2025-Q3 |
| UBS Group AG | DOUBLED | 4,986 | 13,100 | +162.7% | $8.3K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 126,275 | 77,756 | -38.4% | $72.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 87,938 | 13,800 | -84.3% | $12.9K | 2025-Q1 |
| MORGAN STANLEY | ADD | 4,111 | 5,512 | +34.1% | $5.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 73,077 | 126,275 | +72.8% | $121.2K | 2024-Q4 |
| UBS Group AG | DOUBLED | 344 | 4,986 | +1349.4% | $4.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 34,400 | — | $31.3K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.4/10.
BEARISH
S-3
6/10
Milestone Scientific filed a resale S-3 shelf registration covering 15,925,926 shares (7,962,963 Ini
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
4/10
Milestone Scientific reported Q1 2026 EPS of -$0.01, in line with consensus, and revenue of $2.16M,
May 14, 2026
NEUTRAL
8-K
4/10
Milestone Scientific dismissed CBIZ CPAs and hired Grassi & Co. as its new auditor effective May 15,
May 6, 2026
NEUTRAL
8-K
4/10
Milestone Scientific implemented a stock option exchange program for its CEO and SVP, repricing unde
May 6, 2026
NEUTRAL
8-K
4/10
Milestone Scientific (MLSS) is raising up to $2 million through a private placement of units (common
Apr 21, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$1.00 mean target (Nov 2025)
$1.00 Low
$1.00 High
| Metric | Value |
|---|---|
| Current Price | $0.3860 |
| Target Low | $1.00 |
| Target Mean | $1.00 |
| Target Median | $1.00 |
| Target High | $1.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | 50.0% | +0.0% | — | $0.0B | 7.5% | 2 |
| Next Q 2026-09-30 |
$-0.01 | $-0.01 | $-0.01 | 0.0% | +0.0% | — | $0.0B | 6.3% | 2 |
| Current FY 2026-12-31 |
$-0.04 | $-0.04 | $-0.04 | 42.9% | +11.1% | 0↑ 1↓ | $0.0B | 9.9% | 2 |
| Next FY 2027-12-31 |
$-0.04 | $-0.04 | $-0.03 | 12.5% | +12.5% | — | $0.0B | 14.1% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $-0.010 | |
| 30d ago | $-0.010 | |
| 60d ago | $-0.010 | |
| 90d ago | $-0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 20, 2025 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
| Nov 20, 2024 | Benchmark | REITERATE | Speculative Buy | Speculative Buy |
| Oct 10, 2024 | Benchmark | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
fda
Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
<p align="justify">ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computer
May 14, 2026
earnings
Milestone Scientific Reports Financial Results for First Quarter 2026
<p align="center"><em>Operating Loss Reduced As Company Advances Toward Profitability</em></p>
May 14, 2026
earnings_calendar
MLSS Q1 2026 Earnings Scheduled — 2026-05-14
May 13, 2026
earnings_calendar
MLSS Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
other
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
<p align="left">ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug de
Apr 21, 2026
offering
Milestone Scientific Inc. Completes $2.15 Million Private Placement
Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board <pr
Apr 16, 2026
short_interest
FTD: MLSS — 4,292,594 shares ($1.2M) failed to deliver
Settlement: 20260416, Price: $0.27, FTD Value: $1,159,000.38, MILESTONE SCIENTIFIC INC (NEW)
Mar 31, 2026
earnings
Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
<p align="center"><em>Q4 2025 Marks Transition from Restructuring to Growth</em></p>
Mar 31, 2026
earnings_calendar
MLSS Q4 2025 Earnings Before Market Open — 2026-03-31
Mar 27, 2026
earnings_calendar
MLSS Q4 2025 Earnings Before Market Open — 2026-03-27